Julie Papanek Grant - Mar 1, 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Mar 1, 2023
Transactions value $
-$465,303
Form type
4
Date filed
3/3/2023, 04:48 PM
Previous filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$465K -25K -7.04% $18.61 330K Mar 1, 2023 See Footnote F1, F2, F3
holding DAWN Common Stock 2.36K Mar 1, 2023 See Footnote F4
holding DAWN Common Stock 2.55M Mar 1, 2023 See Footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2022.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.37 to $18.84 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Represents shares held by The Grant Family Delaware Trust Agreement of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or for any other purpose.
F4 Represents shares held by The Adam and Julie Grant Revocable Trust dtd October 13, 2017 of which the Reporting Person and her spouse are co-trustees. The Reporting Person disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.
F5 Represents shares held by Canaan XI L.P. The Reporting Person is a non-managing member of Canaan Partners XI LLC, the general partner of Canaan XI L.P. The Reporting Person does not have voting or dispositive power over any of the shares held directly by Canaan XI L.P. and disclaims beneficial ownership of the shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the shares for purposes of Section 16 of the Act, or for any other purpose.